Home / Centerstage / 2019 / february / Week 3 /
Roche agrees to acquire biotechnology firm Spark Therapeutics, based in Philadelphia, to expand its presence in treating hemophilia. The deal is valued at $4.8 billion and is expected to close in the second quarter. Roche's acquisition aims to strengthen its portfolio and capabilities in the field of genetic disorders. The agreement reflects the ongoing consolidation and strategic moves within the biotechnology sector.
Friday, 22 February, 2019